News
Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer
In a discussion of the abstract, Ian Krop, MD, PhD, a professor of internal medicine (medical oncology), director of the Clinical Trials Office, chief clinical research officer, and associate director of Clinical Sciences at Yale Cancer Center in New Haven, Connecticut, explained the importance of improving the sensitivity of HER2 testing for patients with breast cancer. “Current IHC testing is relatively poor at distinguishing HER2-low and -ultralow cancers from HER2 0 cancers,” Krop said.
Source: OncLive